GlassScriptPhysician profile
Hannah D Levavi
NPI 1376906776
$4,521.20
in general payments reported to CMS, 2019-2025
15 companies · $3,397 in 2025
The $3,397 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.00 · 2022: $82.95 · 2023: $253 · 2024: $726 · 2025: $3,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,075 · Food and Beverage: $1,986 · Travel and Lodging: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,075.00 |
| Food and Beverage | $1,985.99 |
| Travel and Lodging | $315.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,446.62 | 2024-2025 | Iclusig, Ninlaro |
| Kite Pharma, INC. | $453.27 | 2024-2025 | Yescarta |
| Sobi, INC | $362.57 | 2024-2025 | |
| Daiichi Sankyo INC. | $289.86 | 2025 | Vanflyta |
| Amgen INC. | $173.44 | 2025 | Blincyto |
| Blueprint Medicines Corporation | $126.27 | 2023-2025 | Ayvakit |
| Genzyme Corporation | $116.75 | 2021-2025 | |
| Cti Biopharma Corp. | $115.36 | 2023 | Vonjo |
| Stemline Therapeutics INC. | $103.09 | 2023 | Orserdu |
| Abbvie INC. | $89.95 | 2024 | |
| Seagen INC. | $82.95 | 2022 | |
| Celgene Corporation | $81.57 | 2025 | Reblozyl |
| Syndax Pharmaceuticals, INC. | $30.09 | 2025 | Revuforj |
| Alnylam Pharmaceuticals INC. | $28.15 | 2025 | Amvuttra |
| Glaxosmithkline, LLC. | $21.26 | 2024 | Ojjaara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Levavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.